KELOWNA, BC - Lexaria Bioscience Corp. (NASDAQ:LEXX) announced today that it has completed dosing in an animal study evaluating its DehydraTECH technology with two next-generation GLP-1 drugs, retatrutide and amycretin, according to a press release statement. The company, with a market capitalization of $16 million, has seen its stock gain 7.6% over the past week despite a challenging year that saw shares decline 35%.
The study examined 18 different formulations to assess compatibility of the drugs with Lexaria’s oral delivery technology. Blood samples were collected over a 24-hour period following dosing to measure pharmacokinetic performance of each composition.
Retatrutide, owned by Eli Lilly and Company, is a triple hormone receptor agonist currently administered via weekly injections. The drug has not yet received FDA approval. In recent Phase 3 studies, patients who remained on the drug experienced average weight loss of 28.3%, or 70 pounds. Amycretin is owned by Novo Nordisk.
The study compared tablet formulations to capsules to evaluate differences in drug absorption through the stomach versus the intestine. Most oral GLP-1 peptide drugs currently on the market use pill formulations absorbed primarily through the stomach.
Lexaria is investigating whether its DehydraTECH processing may reduce severity and instances of side effects such as nausea and gastrointestinal issues while maintaining or improving efficacy. Common side effects of GLP-1 drugs include nausea, diarrhea and vomiting.
The study evaluated alternative formulations to the salcaprozate sodium technology used in Novo Nordisk’s oral Rybelsus and Wegovy tablet products. Compositions tested included sodium caprate, which has been shown to influence gastrointestinal absorption.
"We have already established the compatibility of our technology with today’s leading GLP-1 drugs," said Richard Christopher, CEO of Lexaria Bioscience.
The study was self-sponsored and funded from existing corporate resources. According to InvestingPro data, while Lexaria holds more cash than debt on its balance sheet with liquid assets exceeding short-term obligations, the company is quickly burning through cash—a critical consideration as it advances its technology pipeline. Lexaria holds 65 granted patents with additional patents pending worldwide. InvestingPro analysis suggests the stock is currently undervalued, with six additional ProTips available to subscribers.
In other recent news, Lexaria Bioscience Corp. has made significant strides in its research and development efforts. The company has submitted requests for ethics approval for its Human Pilot Study #7, which will evaluate two oral DehydraTECH-semaglutide compositions against Novo Nordisk’s Wegovy tablets. This comes alongside the completion of final laboratory tablet composition work and commercial-scale manufacturing, with quality-control testing currently underway. Additionally, Lexaria announced an extension of its Material Transfer Agreement with an unnamed pharmaceutical company until December 31, 2026, to further evaluate its DehydraTECH technology in a pre-clinical setting.
The company has also engaged a contract research organization to conduct the aforementioned Human Pilot Study #7, reinforcing its commitment to advancing its drug delivery technology. In a related development, Lexaria has received five new patents, including two for diabetes treatments using GLP-1 drugs. These patents expand Lexaria’s intellectual property portfolio, which already includes patents in the U.S. and Europe.
Meanwhile, Eli Lilly and Company’s Foundayo, an oral GLP-1 agonist tablet, received FDA approval for controlling obesity and weight-related medical conditions in adults. This approval highlights the growing interest and competition in the GLP-1 market, where Lexaria is actively developing its technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.